Chronic Fatigue Drug Moving Slowly: Ampligen Gets "Complete Response"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's "complete response" letter for Hemispherx Biopharma's Ampligen cites the full gamut of problems that could have come up for the NDA
You may also be interested in...
Hemispherx Hopes To Ride Retrovirus Discovery To Ampligen Approval
One year after receiving an extensive “complete response” letter for the chronic fatigue syndrome therapy Ampligen (rintatolimod), Hemispherx Biopharma, Inc. is working to revivify the drug’s clinical prospects by applying recent discoveries about the potential role of a retrovirus in CFS to its dataset.
Hemispherx Hopes To Ride Retrovirus Discovery To Ampligen Approval
One year after receiving an extensive “complete response” letter for the chronic fatigue syndrome therapy Ampligen (rintatolimod), Hemispherx Biopharma, Inc. is working to revivify the drug’s clinical prospects by applying recent discoveries about the potential role of a retrovirus in CFS to its dataset.
Hemispherx’s Ampligen Poised To Become First Approval For Chronic Fatigue Syndrome
FDA staff scheduling changes are behind a 1-2 week delay of action on May 25 user fee goal.